Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

23.41 -0.15 (-0.64%)
Streaming Delayed Price Updated: 9:50 AM EST, Nov 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
News headline image
Why Acadia Pharma Shares Are Falling Today ↗
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced topline results from a Phase 2 trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers Rockwell Medical (NASDAQ:RMTI) stock rose 9.2% to $0.4 during Monday's after-market session. The company's market cap stands at $37.5 million. 
Via Benzinga
News headline image
Acadia Pharmaceuticals Announces Top-Line Results from Phase 2 Study Evaluating ACP-044 for the Treatment of Acute Postoperative Pain
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
28 Biggest Movers From Yesterday ↗
Gainers SailPoint Technologies Holdings, Inc. (NYSE: SAIL) shares jumped 29.16% to close at $64.05 on Monday after private equity firm Thoma Bravo announced plans to acquire... 
Via Benzinga
News headline image
Earnings Scheduled For February 28, 2022 ↗
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
News headline image
Expert Ratings For ACADIA Pharmaceuticals ↗
ACADIA Pharmaceuticals (NASDAQ:ACAD) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Stocks That Hit 52-Week Highs On Thursday ↗
On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight ↗
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that... 
Via Benzinga
News headline image
Acadia: Helping With Alzheimers And Parkinsons ↗
Things always change fast in biotech, but until recently things have been moving consistently to the downside. It’s been a while, but we believe this is finally over. And we believe Acadia... 
Via Talk Markets
News headline image
Stocks And Oil Drop Following The Weak Job Report ↗
It was a strange day for the market that started with a big miss on the ADP job report. 
Via Talk Markets
News headline image
9 Monster Stock Market Predictions For The Week Of March 28 ↗
It will be a critical week for stocks after weeks of gains. The S&P 500 finished Friday in an exciting spot and at more than one inflection point. It may mark the start of a bigger run higher to the... 
Via Talk Markets
News headline image
Acadia Pharmaceuticals Stock Shows Market Leadership With Jump To 91 RS Rating ↗
Acadia Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 88 to 91. 
Via Investor's Business Daily
News headline image
Acadia Pharmaceuticals to Present Late-Breaking Data at the 2022 American Academy of Neurology Annual Meeting (AAN)
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Wednesday Top Stock News: 8 Analyst Upgrades and Downgrades Today ↗
We're taking a look at the top stock news for Wednesday and that includes the latest analysts upgrades and downgrades you need to know about! 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2022 ↗
Upgrades Bernstein upgraded the previous rating for Stryker Corp (NYSE:SYK) from Market Perform to Outperform. For the fourth quarter, Stryker had an EPS of $2.71, compared to... 
Via Benzinga
News headline image
A Peek Into The Markets: US Stock Futures Gain; All Eyes On Fed Decision ↗
Pre-open movers U.S. stock futures traded higher in early pre-market trade ahead of the interest rate decision from the Federal Reserve. Investors are awaiting earnings results... 
Via Benzinga
News headline image
Expert Ratings For ACADIA Pharmaceuticals ↗
Over the past 3 months, 18 analysts have published their opinion on ACADIA Pharmaceuticals (NASDAQ:ACAD) stock. These analysts are typically employed by large Wall Street banks... 
Via Benzinga
News headline image
Recap: ACADIA Pharmaceuticals Q4 Earnings ↗
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q4 earnings results on Monday, February 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
News headline image
Acadia Resubmits Pimavanserin US Application For Expanded Use In Alzheimer's Psychosis ↗
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has resubmitted its FDA supplemental marketing application for pimavanserin for hallucinations and delusions associated... 
Via Benzinga
News headline image
Acadia Pharmaceuticals Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) to Treat Alzheimer’s Disease Psychosis
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Acadia Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 9, 2022 ↗
Upgrades According to Capital One, the prior rating for Federal Realty Investment Trust (NYSE:FRT) was changed from Equal-Weight to Overweight. Federal Realty Investment... 
Via Benzinga
News headline image
Bear Market Bets In Biotech ↗
Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020. 
Via Talk Markets
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
Via Benzinga
News headline image
Acadia, Stoke Team Up In $900M+ Deal On RNA Therapies For CNS Disorders ↗
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) and Stoke Therapeutics Inc (NASDAQ: STOK) will team up on the treatments in rare genetic neurodevelopmental diseases of... 
Via Benzinga
News headline image
Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
From Acadia Pharmaceuticals Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022 ↗
Upgrades According to TD Securities, the prior rating for Canada Goose Holdings Inc (NYSE: 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.